AZD-5672 | AZD-5672 : Antagonist of CCR5
RATINGS:
Cellular Use: (0 reviews)

In Model Organisms: (0 reviews)
Control Compounds

Probe Summary

Targets Biochemical/Biophysical Potency Cellular Potency
CCR5
  • IC50:0.26 nM
  • IC50:0.69 nM
  • Activity:0.76 nM
Antagonist
up to 100 nM

Selectivity

In Vitro Selectivity Assessment
Selectivity Assessment Description:
weak or no inhibition of the 5 major cytochrome P450 (CYP) isoforms, with IC50s for CYP1A1, CYP2C9, ...

Potency
Cellular
In Vitro

CCR5

Mode of Action: Antagonist

Structure-Activity-Relationship data available? Yes

DOI Reference: 10.1016/j.bmcl.2011.12.117

In Vivo Validations

Rat
Dose: 1-2 mg/Kg
Route of delivery: Intravenous
Plasma half life: 2.1 h
Systemic clearance: 38 mL/min/Kg
Volume of Distribution at Steady-State: 5.0 L/Kg

DOI Reference: 10.1016/j.bmcl.2011.12.117

Dose: 2-5 mg/Kg
Route of delivery: Oral
Bioavailability: 41%

DOI Reference: 10.1016/j.bmcl.2011.12.117

Dog
Dose: 1-2 mg/Kg
Route of delivery: Intravenous
Plasma half life: 3.8-3.9 h
Systemic clearance: 15-22 mL/min/Kg
Volume of Distribution at Steady-State: 4.5-5.8 L/Kg

DOI Reference: 10.1016/j.bmcl.2011.12.117

Dose: 2-5 mg/Kg
Route of delivery: Oral
Bioavailability: 46-51%

DOI Reference: 10.1016/j.bmcl.2011.12.117

Chemical Information

Molecular Formula C32H44F2N2O5S2
SMILEs CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@@H](c2cc(F)cc(F)c2)C2CCC(S(C)(=O)=O)CC2)CC1
InChI InChI=1S/C32H44F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-6,9-10,20-22,24,28,30-31H,4,7-8,11-19H2,1-3H3/t24?,30?,31-/m1/s1
Molecular weight 638.27 Da
AlogP 5.001
HBond acceptors 7
HBond donors --
Atoms 87

References

Cross References

canSARChEMBLBindingDB

Vendors

Note: This is not an exhaustive list and does not indicate endorsement by the portal.

Expert Reviews


No SERP comments found for AZD-5672

Probe AZD-5672 is in the process of SERP review.

Please continue to check back for new reviews and commentary.